Stockreport

New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management [Yahoo! Finance]

Alnylam Pharmaceuticals, Inc.  (ALNY) 
Last alnylam pharmaceuticals, inc. earnings: 2/6 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.alnylam.com/investor-overview
PDF - Findings Reinforce Consistent Benefits of Vutrisiran Across ATTR-CM Disease Spectrum, Including Patients with Most Advanced Disease and Diastolic Dysfunction - - Re [Read more]